RxDoctor Payments DataLook up a doctor →

Oleksandra Dryn, MD

Neurology · Cordova, TNNPI 1366861510

Payments from drug & device makers

$2,816,449in general payments, 2019–2025

Across 1,584 payments — averaging $1778.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.6M
  • Ipsen Innovation$103K
  • Avid Radiopharmaceuticals, Inc.$39K
  • AbbVie$3K
  • Novartis$2K
  • EMD Serono, Inc.$2K
  • plus $19K from 54 others
$87,860in research payments, 2019–2025

Across 5 payments — averaging $17,572 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$88K

What the payments were for

  • Speaking & faculty fees$2781%
  • Travel & lodging$6412%
  • Food & beverage$25,02096%
  • Education$1130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly14$2,648,514
Ipsen Innovation110$103,182
Avid Radiopharmaceuticals, Inc.1$38,997
AbbVie(2 entities)337$3,236
Novartis103$1,629
EMD Serono, Inc.57$1,535
Amgen(2 entities)87$1,485
UCB, Inc.55$1,380
AstraZeneca(2 entities)39$1,204
MDD US Operations, LLC19$1,066
Neurocrine Biosciences, Inc.53$1,008
Amneal Pharmaceuticals LLC48$922
Teva Pharmaceuticals USA, Inc.54$915
Genentech USA, Inc.44$866
TG Therapeutics, Inc.27$864
Pfizer90$846
Argenx US, Inc.32$814
Bristol Myers Squibb40$647
Lilly USA, LLC38$614
SK Life Science, Inc.33$609
Biogen33$608
Lundbeck LLC24$525
Biohaven Pharmaceutical Holding Company Ltd.16$352
Eisai Inc.13$341
Alnylam Pharmaceuticals Inc.15$291
Acorda Therapeutics, Inc14$262
CSL Behring14$215
Biohaven Pharmaceuticals, Inc.12$193
Banner Life Sciences, LLC12$189
Neurelis, Inc.11$189
Akcea Therapeutics, Inc.6$170
Otsuka America Pharmaceutical, Inc.7$165
Harmony Biosciences LLC8$163
Jazz Pharmaceuticals Inc.8$158
Averitas Pharma Inc.2$156
Axsome Therapeutics, Inc.2$147
E.r. Squibb & Sons, L.L.C.3$142
Sunovion Pharmaceuticals Inc.8$131
Tanabe Pharma America, Inc.8$119
Sanofi5$118
C2n Diagnostics, LLC6$103
Upsher-smith Laboratories LLC6$99
Merz Pharmaceuticals, LLC4$94
Kyowa Kirin, Inc.6$93
Mallinckrodt Hospital Products Inc.5$88
Adamas Pharmaceuticals, Inc.4$81
Catalyst Pharmaceuticals, Inc.5$81
Acadia Pharmaceuticals Inc5$77
Avanir Pharmaceuticals, Inc.5$71
Scilex Pharmaceuticals Inc.4$69
Insightec,inc1$67
ANI Pharmaceuticals, Inc.3$66
Supernus Pharmaceuticals, Inc.3$54
Takeda Pharmaceuticals U.S.A., Inc.2$53
Avion Pharmaceuticals3$48
Ipsen Biopharmaceuticals, Inc2$46
Boston Scientific2$41
Sobi, Inc2$34
GRT US Holding, Inc.2$29
Nevro Corp.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,816,449 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$235,582
Medicare patients
391
Services billed
24,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4623$410,318
OctagamImmun Globg(Igg)/Malt/Iga Ov5014$242,003
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$108,477
BotoxOnabotulinumtoxina14$31,945
Memantine Hcl188$7,972
Donepezil Hcl88$3,108
Gabapentin206$2,922
Lacosamide24$2,907
Pyridostigmine Bromide17$1,739
Carbidopa-LevodopaCarbidopa/Levodopa78$1,425
Pregabalin62$1,229
Mycophenolate Mofetil15$1,208
Levetiracetam41$968
Primidone22$814
Oxcarbazepine11$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$846$242,00314 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$53$108,47726 claims
AbbVieBotox$3,236$31,94514 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$922$2,94832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.

Other neurology in Cordova

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →